Here's some other vaccine news of note for the week.
> A phase 3 study showed that GlaxoSmithKline's Shingrix is effective for adults 18 and older after they have undergone an autologous hematopoietic stem cell transplant. Release
> Seqirus is investing $9 million to expand its North Carolina flu vaccine manufacturing plant. NCBiotech story
> Aduro is giving up on its most advanced cancer vaccine program. Endpoints News story
> Formerly a subsidiary of Valneva, Maryland's Intercell changed its name to Valneva USA and is taking over marketing and distribution rights for Japanese encephalitis vaccine Ixiaro. Release